We are live on ! Find out more
ALBO

Albireo Pharma Inc
ALBO

Delisted

ALBO was delisted on the 2nd of March, 2023.

Back to rankings

109 hedge funds and large institutions have $495M invested in Albireo Pharma Inc in 2022 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 30 increasing their positions, 39 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,633% more call options, than puts

Call options by funds: $8.42M | Put options by funds: $486K

300% more funds holding in top 10

Funds holding in top 10: 1 → 4 (+3)

163% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 8

37% more capital invested

Capital invested by funds: $362M → $495M (+$133M)

14% more funds holding

Funds holding: 96 → 109 (+13)

23% less repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 39

Holders
109
Holders Change
+13
Holders Change %
+13.54%
% of All Funds
1.72%
Holding in Top 10
4
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+300%
% of All Funds
0.06%
New
21
Increased
30
Reduced
39
Closed
8
Calls
$8.42M
Puts
$486K
Net Calls
+$7.93M
Net Calls Change
+$6.83M

Top Buyers

Rank Fund Capital Flow
1
TCM
Tang Capital Management
California
+$13.7M
2
NIP
Nicholas Investment Partners
California
+$12.9M
3
O
OrbiMed
New York
+$5.68M
4
Franklin Resources
Franklin Resources
California
+$5.1M
5
CC
Chicago Capital
Illinois
+$4.76M

Top Sellers

Rank Fund Capital Flow
1
AG
Artal Group
Luxembourg
-$14M
2
Millennium Management
Millennium Management
New York
-$4.6M
3
Goldman Sachs
Goldman Sachs
New York
-$3.75M
4
Marshall Wace
Marshall Wace
United Kingdom
-$3.01M
5
State Street
State Street
Massachusetts
-$2.46M
Name Holding Trade Value Shares
Change 		Change in
Stake
M&T Bank
51
M&T Bank
New York
$606K +$297K +10,150 +100%
AA
52
ALPS Advisors
Colorado
$594K -$70.5K -2,407 -11%
MAM
53
Martingale Asset Management
Massachusetts
$577K – – –
Connor, Clark & Lunn Investment Management (CC&L)
54
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$543K +$42.2K +1,440 +9%
RhumbLine Advisers
55
RhumbLine Advisers
Massachusetts
$536K +$6.32K +216 +1%
SFI
56
Susquehanna Fundamental Investments
Pennsylvania
$400K – – –
HF
57
HRT Financial
New York
$394K -$48.2K -1,645 -11%
State Board of Administration of Florida Retirement System
58
State Board of Administration of Florida Retirement System
Florida
$390K – – –
CL
59
CSS LLC
Illinois
$390K +$73.2K +2,500 +24%
CSS
60
Cubist Systematic Strategies
Connecticut
$327K +$293K +10,006 +1,033%
CS
61
Credit Suisse
Switzerland
$324K +$21.5K +734 +7%
MIM
62
MetLife Investment Management
New Jersey
$294K +$101K +3,466 +54%
Deutsche Bank
63
Deutsche Bank
Germany
$286K -$31.6K -1,080 -10%
Renaissance Technologies
64
Renaissance Technologies
New York
$286K +$281K +9,600 New
AI
65
AdvisorShares Investments
Maryland
$270K +$265K +9,066 New
Citigroup
66
Citigroup
New York
$261K -$1.27M -43,449 -83%
AIG
67
American International Group
New York
$250K -$17.2K -589 -7%
E
68
Ergoteles
New York
$247K +$243K +8,288 New
GC
69
Grimes & Company
Massachusetts
$244K +$240K +8,191 New
JP Morgan Chase
70
JP Morgan Chase
New York
$239K +$39.3K +1,341 +20%
BC
71
Burney Company
Virginia
$238K +$234K +7,976 New
Manulife (Manufacturers Life Insurance)
72
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$222K -$67.6K -2,309 -24%
UBS AM
73
UBS AM
Illinois
$219K +$215K +7,337 New
Invesco
74
Invesco
Georgia
$203K +$198K +6,780 New
VOYA Investment Management
75
VOYA Investment Management
Georgia
$202K +$198K +6,772 New
1 2
3
4 5

ALBO Hedge Fund Activity: Q1 2022 in Review

109 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Albireo Pharma Inc (ALBO) for Q1 2022, worth a combined $495M — up 37% from $362M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new ALBO positions and 8 closed out — a net gain of 13 holders — while 30 added to existing stakes and 39 trimmed.

The largest buyer was Tang Capital Management, opening a new position worth an estimated $13.7M. The largest seller was Artal Group, exiting entirely with an estimated $14M sold.

  • 109 institutional investors held Albireo Pharma Inc (ALBO) as of Q1 2022, up from 96 in Q4 2021.
  • Funds reported $495M of Albireo Pharma Inc stock for Q1 2022, up 37% quarter-over-quarter.
  • 21 funds opened new Albireo Pharma Inc positions in Q1 2022 and 8 closed out, a net change of +13 holders.
  • The largest Albireo Pharma Inc buyer in Q1 2022 was Tang Capital Management, an estimated $13.7M added.
  • The largest Albireo Pharma Inc seller in Q1 2022 was Artal Group, an estimated $14M sold.

Based on aggregated 13F filings for Q1 2022.